CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How?
Mené sur 322 patients atteints d'un lymphome agressif à cellules B réfractaire ou en progression dans les 12 mois suivant le traitement de première ligne, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité du tisagenleleucel (une immunothérapie à base de lymphocytes CAR-T ciblant CD19) en traitement de deuxième ligne
Large B-cell lymphoma is a spectrum of aggressive B-cell cancers with broad genetic and clinical heterogeneity.1 First-line chemotherapy cures most patients, but those with relapsed or refractory disease usually die of lymphoma. Salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) is the standard second-line approach to large B-cell lymphoma and cures up to 30 to 40% of eligible patients, but it is restricted to younger, fit patients and is relatively ineffective in chemotherapy-refractory disease.2 Chimeric antigen receptor (CAR) T-cell therapies that target CD19 have advanced the treatment of multiply relapsed large B-cell lymphoma and showed promising rates of durable remission . . .
New England Journal of Medicine , éditorial, 2020